MMP9 is decreased in natalizumab-treated MS patients at risk for PML - Université Pierre et Marie Curie Accéder directement au contenu
Article Dans Une Revue Annals of Neurology Année : 2017

MMP9 is decreased in natalizumab-treated MS patients at risk for PML

Nicolas Fissolo
  • Fonction : Auteur
Béatrice Pignolet
Clara Matute-Blanch
  • Fonction : Auteur
Juan Carlos Triviño
  • Fonction : Auteur
Berta Miró
  • Fonction : Auteur
Miriam Mota
  • Fonction : Auteur
Laurent Almoyna
  • Fonction : Auteur
Best-Ms Bionat
  • Fonction : Auteur
Sfsep Network
  • Fonction : Auteur

Résumé

OBJECTIVE: To identify biomarkers associated with the development of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with natalizumab (NTZ). METHODS: Relapsing-remitting MS (RRMS) patients who developed PML under NTZ therapy (pre-PML) and non-PML natalizumab-treated patients (NTZ-ctr) were included in the study. Cryopreserved peripheral blood mononuclear cells (PBMC) and serum samples collected at baseline, at one- and two-year treated time points, and during PML were analyzed for gene expression by RNA-sequencing and for serum protein levels by LUMINEX and ELISA assays respectively. RESULTS: Among top differentially expressed genes in the RNA-sequencing between pre-PML and NTZ-ctr patients, pathway analysis revealed a high representation of genes belonging to the following categories: pro-angiogenic factors (MMP9, VEGFA), chemokines (CXCL1, CXCL5, IL8, CCL2), cytokines (IL1B, IFNG), and plasminogen- and coagulation-related molecules (SERPINB2, PLAU, PLAUR, TFPI, THBD). Serum protein levels for these candidates were measured in a two-step manner in a screening cohort and a validation cohort of pre-PML and NTZ-ctr patients. Only MMP9 was validated and, in pre-PML patients MMP9 protein levels were significantly reduced at baseline compared with NTZ-ctr patients and levels remained lower at later time points during NTZ treatment. INTERPRETATION: The results from this study suggest that the pro-angiogenic factor MMP9 may play a role as biomarker associated with the development of PML in MS patients treated with NTZ. This article is protected by copyright. All rights reserved.

Mots clés

snc
Fichier non déposé

Dates et versions

hal-01657971 , version 1 (07-12-2017)

Identifiants

Citer

Nicolas Fissolo, Béatrice Pignolet, Clara Matute-Blanch, Juan Carlos Triviño, Berta Miró, et al.. MMP9 is decreased in natalizumab-treated MS patients at risk for PML. Annals of Neurology, 2017, ⟨10.1002/ana.24987⟩. ⟨hal-01657971⟩
89 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More